Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2017
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-convertersNicholas Schwab, Tilman Schneider-Hohendorf, Tammy Hoyt, et al.
Undersea & Hyperbaric Medicine : Journal of the Undersea and Hyperbaric Medical Society, Inc|May 21, 2013
A prospective trial of hyperbaric oxygen for chronic sequelae after brain injury (HYBOBI)Susan Churchill, Lindell K Weaver, Kayla Deru, et al.
Brain Communications|January 9, 2024
Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosisWen Zhu, Chenyi Chen, Lili Zhang, et al.
Molecular Pharmacology|August 29, 2015
Selectivity in the Use of Gi/o Proteins Is Determined by the DRF Motif in CXCR6 and Is Cell-Type SpecificSatya P Singh, John F Foley, Hongwei H Zhang, et al.
Science (New York, N.Y.)|March 2, 2023
In Science JournalsBianca Lopez, Jelena Stajic, John F Foley, et al.
Science (New York, N.Y.)|October 12, 2023
In Science JournalsBrent Grocholski, Mattia Maroso, Jake S Yeston, et al.
Science (New York, N.Y.)|June 29, 2023
In Science JournalsBianca Lopez, Di Jiang, Keith T Smith, et al.
Science (New York, N.Y.)|September 28, 2023
In Science JournalsKip Hodges, Ian S Osborne, Daniela Neuhofer, et al.
Science (New York, N.Y.)|April 6, 2023
In Science JournalsCourtney S Malo, Priscilla N Kelly, Yury Suleymanov, et al.
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
Pageof 12